Abstract
We describe the institutional guidelines of a major tertiary cancer center with regard to using hypofractionated radiation regimens to treat glioblastoma as a measure to minimize exposure to coronavirus disease 2019 (COVID-19) while not sacrificing clinical outcomes. Our guidelines review level one evidence of various hypofractionated regimens, and recommend a multidisciplinary approach while balancing the risk of morbidity and mortality among individuals at high risk for severe illness from COVID-19 infection. We also briefly outline strategies our department is taking in mitigating risk among our cancer patients undergoing radiation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 743-745 |
| Number of pages | 3 |
| Journal | Advances in Radiation Oncology |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2020 |
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
MD Anderson CCSG core facilities
- Clinical Trials Office
Fingerprint
Dive into the research topics of 'Radiation for Glioblastoma in the Era of Coronavirus Disease 2019 (COVID-19): Patient Selection and Hypofractionation to Maximize Benefit and Minimize Risk'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS